BeOne Medicines Quarterly Cash Flow Statement
NASDAQ: ONCHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BeOne Medicines free cash flow
In the quarter ended Jun 30, 2026, BeOne Medicines generated $462.8 million of operating cash flow and spent $27.5 million on capital expenditures. That left free cash flow of $435.3 million, a free-cash-flow margin of 25.5% of revenue. Free cash flow was up 98.1% from the prior year's $219.8 million.
Summary generated from market data by MetaCap's automated system. Methodology
BeOne Medicines cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 237.01M | 227.36M | 66.50M | 124.84M | 94.32M | 1.27M | -151.88M | -121.35M | -120.41M | -251.15M | -367.55M | 215.41M |
| Net Income growth (YoY) | +151.28% | +17802.13% | — | — | — | — | — | -156.33% | — | — | — | — |
| Depreciation & Amortization | 40.52M | 41.14M | 35.98M | 37.28M | 35.61M | 32.80M | 50.25M | 71.29M | 24.93M | 25.29M | 23.82M | 21.51M |
| Stock-Based Compensation | 137.41M | 123.36M | 123.76M | 140.81M | 150.81M | 95.48M | 107.62M | 114.70M | 130.64M | 88.67M | 92.92M | 96.00M |
| Change in Working Capital | -142.69M | -172.32M | 16.38M | 9.76M | -122.63M | -25.67M | -76.06M | 47.83M | -164.25M | -76.05M | -113.00M | -116.33M |
| Operating Cash Flow | 462.82M | 201.34M | 417.35M | 402.55M | 263.60M | 44.08M | 75.16M | 188.37M | -95.59M | -308.57M | -221.64M | -78.15M |
| Capital Expenditures | -27.48M | -40.79M | -37.52M | -48.08M | -43.83M | -56.41M | -92.48M | -133.66M | -109.95M | -156.58M | -156.96M | -157.88M |
| Investing Cash Flow | -49.35M | -45.51M | -38.34M | -49.27M | -66.61M | -121.94M | -93.61M | -133.88M | -111.03M | -209.83M | -62.58M | -186.28M |
| Debt Repaid | -17.05M | -7.64M | -14.62M | -4.26M | -12.58M | -4.21M | -10.45M | -3.56M | -10.44M | -3.58M | -5.23M | -8.46M |
| Financing Cash Flow | -6.05M | 68.63M | 96.93M | 961.27M | 35.02M | -33.78M | -4.52M | 12.66M | 23.02M | 162.29M | 347.05M | -76.78M |
| Net Change in Cash | 427.25M | 243.78M | 499.11M | 1.32B | 255.50M | -108.16M | -74.68M | 95.50M | -189.50M | -378.55M | 105.09M | -340.68M |
| Free Cash Flow | 435.34M | 160.55M | 379.82M | 354.47M | 219.77M | -12.32M | -17.32M | 54.71M | -205.54M | -465.15M | -378.60M | -236.03M |
This table shows 12 quarterly periods of BeOne Medicines's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ONC's reporting calendar. What is a cash flow statement?